share_log

Zevra Therapeutics Says Arimoclomol Research Featured In Two Poster Presentations At 19th Annual WORLDSymposium 2023

Benzinga ·  Feb 24, 2023 07:37

Interim data analysis of four-year, open-label extension from Phase 2/3 clinical trial suggests arimoclomol may reduce long-term progression of Niemann-Pick Disease Type C (NPC)

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment